Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Not Confirmed
Not Confirmed
12-14 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Not Confirmed
12-14 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
06 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/neurotherapia-raises-12-3m-in-the-first-close-of-its-series-b-financing-302213518.html
08 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/neurotherapia-receives-grant-from-alzheimers-association-for-development-of-first-in-class-drug-for-alzheimers-disease-302139707.html
24 Oct 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/10/24/2765493/0/en/NeuroTherapia-Presents-Clinical-Data-from-Phase-1b-Clinical-Trial-of-NTRX-07-for-the-Treatment-of-Alzheimer-s-Disease.html
02 Dec 2020
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/neurotherapia-announces-completion-of-phase-1a-clinical-trial-301179041.html
01 Dec 2020
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/neurotherapia-announces-completion-of-phase-1a-clinical-trial-301179041.html
Details:
NeuroTherapia will use this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer's disease
Lead Product(s): NTRX-07
Therapeutic Area: Neurology Brand Name: NTRX-07
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Cleveland Clinic
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 06, 2024
Lead Product(s) : NTRX-07
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Cleveland Clinic
Deal Size : $12.3 million
Deal Type : Series B Financing
NeuroTherapia Raises $12.3M in the First Close of its Series B Financing
Details : NeuroTherapia will use this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer's disease
Brand Name : NTRX-07
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 06, 2024
Details:
The net proceeds will be used for the development of its first-in-class drug, NTRX-07, a novel drug that targets neuroinflammation, for the treatment of Alzheimer's disease.
Lead Product(s): NTRX-07
Therapeutic Area: Neurology Brand Name: NTRX-07
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Alzheimer's Association
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 08, 2024
NeuroTherapia Receives Grant from Alzheimer's Association for its Alzheimer’s Drug
Details : The net proceeds will be used for the development of its first-in-class drug, NTRX-07, a novel drug that targets neuroinflammation, for the treatment of Alzheimer's disease.
Brand Name : NTRX-07
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 08, 2024
Details:
NeuroTherapia is currently completing its first-in-human clinical trial using NTRX-07 with funding provided in part by a grant from the Alzheimer's Association. The company will use the Series A funds to finish this work while also undertaking a number of preclinical studies.
Lead Product(s): NTRX-07
Therapeutic Area: Neurology Brand Name: NTRX-07
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Brain Trust Accelerator Fund II
Deal Size: $8.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 22, 2020
NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II
Details : NeuroTherapia is currently completing its first-in-human clinical trial using NTRX-07 with funding provided in part by a grant from the Alzheimer's Association. The company will use the Series A funds to finish this work while also undertaking a number o...
Brand Name : NTRX-07
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 22, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?